Organon (OGN) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Organon (OGN) over the past year, gaining 199.5% versus a gain of 34.3%. Over five years, TNGX leads with a +55.6% price change compared with -60.6% for OGN. Tango Therapeutics is the larger company by market cap ($3.81 billion vs $3.61 billion), about 1.1 times the size.
Organon pays a dividend yielding 0.58%, while Tango Therapeutics does not currently pay one. Organon converts more of its revenue into profit, with a net margin of 3.0% versus -162.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGN | TNGX |
|---|---|---|
| Share price | $13.75 | $22.57 |
| Market cap | $3.61B | $3.81B |
| 1-day change | -0.29% | +3.39% |
| YTD return | +91.77% | +146.39% |
| 1-year return | +34.28% | +199.45% |
| 5-year return | -60.59% | +55.60% |
| P/E ratio (TTM) | 17.63 | — |
| Forward P/E | 3.80 | — |
| EPS (TTM) | $0.78 | $-0.85 |
| Dividend yield | 0.58% | 0.00% |
| Annual dividend | $0.08 | $0.00 |
| Revenue (latest FY) | $6.22B | $62.38M |
| Revenue growth (YoY) | -2.92% | +48.29% |
| Net income (latest FY) | $187.00M | $-101.59M |
| Gross margin | 53.30% | — |
| Operating margin | — | -178.39% |
| Net margin | 3.01% | -162.85% |
| 52-week high | $13.80 | $34.39 |
| 52-week low | $5.69 | $6.69 |
| Distance from 52-week high | -0.36% | -34.37% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -18.18% | +100.18% |
| Average volume | 2.64M | 2.61M |
| Shares outstanding | 262.61M | 168.61M |
| Employees | 10,000 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed OGN by 165.2 percentage points over the past year.
- Organon is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -162.9 cents for Tango Therapeutics.
- Tango Therapeutics grew revenue faster in its latest fiscal year (+48.29% vs -2.92%).
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
OGN vs TNGX FAQ
Which is bigger, Organon or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.81B compared with $3.61B for Organon (OGN).
Which stock has performed better over the past year, OGN or TNGX?
TNGX returned +199.45% over the past 12 months, compared with +34.28% for OGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Organon or Tango Therapeutics?
Organon pays a dividend yielding 0.58%, while Tango Therapeutics does not currently pay a regular dividend.
Are Organon and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.